SWIM vs LEXX

For growth investors, Lexaria Bioscience Corp.

(LEXX) is the stronger pick with 52. 0% revenue growth year-over-year, versus 7. 4% for Latham Group, Inc. (SWIM). Latham Group, Inc. (SWIM) offers the better valuation at 62. 0x trailing P/E (34. 4x forward), making it the more compelling value choice. Analysts rate Latham Group, Inc. (SWIM) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Latham Group, Inc.

(SWIM) delivered a total return of -80. 1%, compared to -89. 8% for Lexaria Bioscience Corp. (LEXX). Over 10 years, the gap is even starker: SWIM returned -78. 9% versus LEXX's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lexaria Bioscience Corp.

(LEXX) is the lower-risk stock at 1. 00β versus Latham Group, Inc. 's 2. 11β — meaning SWIM is approximately 112% more volatile than LEXX relative to the S&P 500. On balance sheet safety, Lexaria Bioscience Corp. (LEXX) carries a lower debt/equity ratio of 4% versus 9% for Latham Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lexaria Bioscience Corp.

(LEXX) is pulling ahead at 52. 0% versus 7. 4% for Latham Group, Inc. (SWIM). On earnings-per-share growth, the picture is similar: Latham Group, Inc. grew EPS 161. 9% year-over-year, compared to -40. 4% for Lexaria Bioscience Corp.. Over a 3-year CAGR, LEXX leads at 40. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Latham Group, Inc.

(SWIM) is the more profitable company, earning 2. 0% net margin versus -1686. 0% for Lexaria Bioscience Corp. — meaning it keeps 2. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SWIM leads at 5. 8% versus -1648. 0% for LEXX. At the gross margin level — before operating expenses — LEXX leads at 83. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lexaria Bioscience Corp.

(LEXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00)). Latham Group, Inc. (SWIM) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEXX: -85. 7%, SWIM: -78. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SWIM (Industrials) and LEXX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SWIM is a small-cap quality compounder stock; LEXX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.